Xbrane Biopharma AB/News/Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023

29 May 2023 - 16:20

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Wednesday, May 31th, 2023, at 11.00 a.m. CET. Xbrane will publish the company’s interim report January – March 2023, on Wednesday, May 31, 2023, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – March 2023, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
https://ir.financialhearings.com/xbrane-biopharma-q1-2023

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5002104

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Provided by: MFN

Xbrane Biopharma AB

Xbrane Biopharma develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion....

Learn more about company

Related news

21.09.2023

Stayble Therapeutics AB

Stayble Therapeutics presents at Financial Stockholm's investor meeting on September 25, 2023

On Monday, September 25, Stayble will be one of several companies presenting at Financial Stockholm's investor meeting at Scandic Anglais in Stockholm. At 17:50, Stayble's CEO, Andreas Gerward, will share insights about the Company's latest progress, future plans, and how Stayble is work...

21.09.2023

Stayble Therapeutics AB

Stayble Therapeutics presenterar på Financial Stockholms investerarträff den 25 september 2023

Måndagen den 25 september kommer Stayble vara ett av flera bolag som presenterar vid Financial Stockholms investerarträff på Scandic Anglais i Stockholm. Klockan 17:50 kommer Staybles VD, Andreas Gerward, att dela insikter om Bolagets senaste framsteg, framtida planer och hur Stayble jobbar mot att...

21.09.2023

Diamyd Medical AB

Kallelse till extra bolagsstämma i Diamyd Medical AB

Deltagande Aktieägare som vill delta i stämman ska dels vara införda i den av Euroclear Sweden AB förda aktieboken måndagen den 2 oktober 2023, dels anmäla sitt deltagande till Diamyd Medical senast onsdagen den 4 oktober 2023 per post på adress Diamyd Medical, Box 7349, 103 90 Stockholm...

21.09.2023

OncoZenge AB

VD köper aktier i OncoZenge

“OncoZenge har gått på några käftsmällar men är positionerad för att adressera ett stort och växande behov för oral smärtlindring. Det känns otroligt meningsfullt att verka för att vår produkt når miljontals patienter s...